Alder Therapeutics is a virtual and agile preclinical phase allogeneic stem cell therapy development company that’s shaping the future of regenerative medicine.
Through our unique cell therapy development philosophy — AlderEdge — we overcome the challenges of traditional development approaches, embedding risk reduction, rigorous planning, and commercial-mindedness at the core of cell therapy programs.
Armed with the AlderEdge approach and an industry-renowned team that understands the commercial challenges of bringing cell therapies to market, we’re on a bold mission to cure the incurable.
We have exclusive IP licenses for state-of-the-art methods to manufacture two promising stem cell therapy products
These therapies have the potential to transform the way we treat two diseases with high global burden and significant unmet need.
What’s more, the treatment of each disease represents a multibillion USD commercial opportunity.
Critically, extensive preclinical tests have already demonstrated proof-of-concept for the two programs.
Now, using the AlderEdge approach, we aim to further improve manufacturing of these therapies and propel them through clinical trials.
To date, we’ve received €3 million in seed funding from the most active and well-respected investment companies in Sweden — Flerie and Linc. We have also successfully raised a substantial sum of non-dilutive funding.
Now, we want to raise €22million to take our lead ALD01 eye cell therapy program through Phase I/IIa clinical trials by 2026, and to take our second ALD02 cardiac program to GLP Tox studies.
Download our investor presentation here:
Embark on a transformative journey with Alder Therapeutics and join us in our mission to cure the incurable.
.png)
.png)
.png)
